v3.23.2
SCHEDULE OF NON CONTROLLING INTEREST (Details) - USD ($)
 3 Months Ended 6 Months Ended 12 Months Ended
Jun. 30, 2023
Mar. 31, 2023
Jun. 30, 2022
Mar. 31, 2022
Jun. 30, 2023
Jun. 30, 2022
Dec. 31, 2022
Dec. 31, 2021
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]                
Net loss attributable to the non-controlling interest $ (764) $ (32,894) $ (11,691) $ (51,116) $ (33,658) $ (62,807) $ (193,372) $ (496,297)
Subsidiaries [Member]                
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]                
Net loss Subsidiary         (121,063)   (817,151) (2,089,253)
Net loss attributable to the non-controlling interest         33,658   193,372 496,297
Net loss affecting Bioxytran         (87,405)   (623,780) (1,592,956)
Accumulated losses         (3,574,358)   (3,594,287) (2,777,135)
Accumulated losses attributable to the non-controlling interest         785,236   751,578 558,206
Accumulated losses Bioxytran         (2,789,122)   (2,842,709) (2,218,929)
Net equity non-controlling interest         $ (624,286)   $ (590,628) $ (397,256)